A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors

Previous analysis of Phase 3 clinical trial data for colorectal cancer patients treated with cetuximab revealed that patients harboring a KRAS mutation did not benefit from treatment. This finding set the stage for one of the first examples of cancer personalized medicine. Confusingly, patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: McFall, Thomas, Stites, Edward Cooper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051129/
https://www.ncbi.nlm.nih.gov/pubmed/32158916
http://dx.doi.org/10.1080/23723556.2019.1701914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051129/
https://www.ncbi.nlm.nih.gov/pubmed/32158916
http://dx.doi.org/10.1080/23723556.2019.1701914

Ejemplares similares